Furthermore, in the ROCKET-AF (The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study, patients with CrCl 30 to 49 mL/min had a numerically lower incidence of stroke/SEEs with rivaroxaban vs warfarin (HR: 0.84; 95% CI: 0.57-1.23).18 This evidence concerns the gene F10 and atrial fibrillation.